Depression is one of the most common of the major psychiatric disorders, with a high life time prevalence. It is known that, although different antidepressants have different putative mechanisms of action, the distinctions between them in terms of efficacy are extremely small. At present no antidepr...
Depression is one of the most common of the major psychiatric disorders, with a high life time prevalence. It is known that, although different antidepressants have different putative mechanisms of action, the distinctions between them in terms of efficacy are extremely small. At present no antidepressant has shown efficacy greater than that of the first-generation compounds, the tricyclic antidepressants(TCAs) and the monoamine oxidase inhibitors. When selecting an antidepressant, several factors such as safety, tolerability, efficacy, cost effectiveness, and simplicity must be considered. Unfortunately, the tricyclic antidepressants have other effects that are not related to their therapeutic activity, including muscarinic, histaminergic, alpha-1-adrenergic blockade. And these actions cause dry mouth, constipation, urinary retention, sedation, orthostatic hypotension, cardiac toxicity and weight gain. Other antidepressants affecting only the serotonin reuptake site have been developed and termed as selective serotonin reuptake inhibitors(SSRis). Several potential benefits may anse from these drugs in the aspects with side effect and tolerability. At present exciting changes are taking place in our uriderstanding of the neurobiology of depression and its treatment. The goal today is development of drugs With affinity for specific sites in the brain that mediate antidepressant activity but without affinity for sites involved in other types of pharmacologic effects. The newest class of antidepressant is the serotonin-noradrenergic reuptake inhibitos(SNRis). These include venlafaxine, duloxeting and milnacipran. Several classes of serotonergic drugs are in development. The 5-HT2 antagonists/5-HT reuptake inhibitors such as nefazodone and mirtazepine have shown evidence of antidepressant activity and possess a good overall tolerability profile. These new-generation antidepressant are expected to offer the potential for efficacy in a broad range of patients, rapid onset of action, and a safety/tolerability profile similar to SSRIs and superior to the TCAs.
Depression is one of the most common of the major psychiatric disorders, with a high life time prevalence. It is known that, although different antidepressants have different putative mechanisms of action, the distinctions between them in terms of efficacy are extremely small. At present no antidepressant has shown efficacy greater than that of the first-generation compounds, the tricyclic antidepressants(TCAs) and the monoamine oxidase inhibitors. When selecting an antidepressant, several factors such as safety, tolerability, efficacy, cost effectiveness, and simplicity must be considered. Unfortunately, the tricyclic antidepressants have other effects that are not related to their therapeutic activity, including muscarinic, histaminergic, alpha-1-adrenergic blockade. And these actions cause dry mouth, constipation, urinary retention, sedation, orthostatic hypotension, cardiac toxicity and weight gain. Other antidepressants affecting only the serotonin reuptake site have been developed and termed as selective serotonin reuptake inhibitors(SSRis). Several potential benefits may anse from these drugs in the aspects with side effect and tolerability. At present exciting changes are taking place in our uriderstanding of the neurobiology of depression and its treatment. The goal today is development of drugs With affinity for specific sites in the brain that mediate antidepressant activity but without affinity for sites involved in other types of pharmacologic effects. The newest class of antidepressant is the serotonin-noradrenergic reuptake inhibitos(SNRis). These include venlafaxine, duloxeting and milnacipran. Several classes of serotonergic drugs are in development. The 5-HT2 antagonists/5-HT reuptake inhibitors such as nefazodone and mirtazepine have shown evidence of antidepressant activity and possess a good overall tolerability profile. These new-generation antidepressant are expected to offer the potential for efficacy in a broad range of patients, rapid onset of action, and a safety/tolerability profile similar to SSRIs and superior to the TCAs.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.